Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

PD and loss of peritoneal function.

A Jörres1, J Witowski, T O Bender

  • 1Department of Nephrology and Medical Intensive Care, Charité University Hospital, Campus Virchow-Klinikum, Berlin, Germany. achim.joerres@charite.de

Prilozi
|October 13, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First look at evaluation of serum angiopoietin-like 4 levels in bladder cancer: A pilot study.

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society·2026
Same author

The multidirectional assessment of moderate caloric restriction and metformin treatment in obese patients.

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society·2024
Same author

Soluble receptor for advanced glycation end products (sRAGE) correlates with obesity-related parameters, and it is not easy to be modified by moderate caloric restriction in obese humans.

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society·2023
Same author

[S3 Guideline Sepsis-prevention, diagnosis, therapy, and aftercare : Long version].

Medizinische Klinik, Intensivmedizin und Notfallmedizin·2020
Same author

[S3 guideline sepsis-prevention, diagnosis, treatment, and aftercare : Summary of the strong recommendations].

Medizinische Klinik, Intensivmedizin und Notfallmedizin·2020
Same author

The role of purinergic P2Y<sub>12</sub> receptor blockers on the angiogenic properties of endothelial cells: an in vitro study.

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society·2018

Long-term peritoneal dialysis can damage the peritoneal membrane, especially with infections and bio-incompatible fluids. New glucose degradation product-depleted dialysis fluids show promise for improving patient outcomes.

Area of Science:

  • Nephrology
  • Biomaterials Science
  • Cell Biology

Background:

  • Long-term peritoneal dialysis (PD) alters peritoneal membrane structure and function.
  • Factors influencing these changes include duration of treatment, infection frequency/severity, and dialysis fluid bio-incompatibility.
  • Glucose degradation products (GDPs) in PD fluids are implicated in impaired peritoneal cell function and advanced glycation end product (AGE) deposition.

Purpose of the Study:

  • To evaluate the impact of new glucose degradation product-depleted peritoneal dialysis fluids on clinical outcomes.
  • To assess the potential of improved PD fluid formulations to mitigate peritoneal membrane damage.

Main Methods:

  • Prospective randomized studies were conducted.
  • Patients received treatment with either conventional or new GDP-depleted PD fluids.

Related Experiment Videos

  • Peritoneal membrane function, cell function, and AGE deposition were assessed over time.

    • Main Results:

    • Treatment with new GDP-depleted PD fluids led to significant improvements in clinical outcomes for PD patients.
    • Reduced GDPs in PD fluids may mitigate peritoneal cell dysfunction and AGE accumulation.
    • These findings suggest a benefit for using advanced PD fluid formulations.

    Conclusions:

    • New glucose degradation product-depleted peritoneal dialysis fluids represent a significant advancement in patient care.
    • Utilizing these novel fluids may enhance the longevity of the peritoneum and improve overall patient prognosis in peritoneal dialysis.
    • Further research should focus on long-term efficacy and safety profiles.